Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Shares gained 22.4% through August 28 as Q2 revenue rose about 38%, testing volumes reached records, and management raised guidance. Japan approval, EU certification, and the expected August 30 Medicare coverage determination provide concrete near-term catalysts.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Liquidity ⢠Narrowing Losses ⢠Negative Free Cash Flow NTRA's strong liquidity and improving operating losses are offset by persistent unprofitability, weakening free cash flow, and elevated valuation multiples, warranting caution.
Price Behavior
Key Price Behavior Insights: ⢠Modest uptrend ⢠Resistance test ⢠Support holding Support Level: $324.00â$326.00 (stronger: $320.00â$322.00) Resistance Level: $336.70â$338.70 NTRA is modestly bullish over the last month, holding above its 21-day average, but needs a sustained break above $336.70â$338.70 to strengthen momentum; watch $324â$326 support.
Sentiment & News
Key News Insights: ⢠Raised Outlook ⢠Signatera Growth ⢠Strategic Partnerships Natera's raised outlook, strong Signatera growth, new oncology partnerships, and institutional buying support bullish momentum, though valuation and regulatory risks remain.
AI Summary
Natera's shift to a scaled diagnostics platform is increasingly validated by Signatera's 57% oncology-volume growth, guideline support, and rising margins, but at ~17x sales investors should own or add only if upcoming reimbursement gains translate into sustained free-cash-flow and operating-leverage proof.
Description
Natera, Inc. is a global molecular diagnostics company that develops and commercializes genomic tests for reproductive health, oncology, transplant monitoring and miscarriage and paternity analysis. The firm also offers cloud-accessible bioinformatics for laboratory customers and distributes its services through a direct sales force and roughly 100 laboratory and distribution partners. Founded in 2003 and based in Austin, Texas, Natera has strategic partnerships with BGI Genomics and Foundation Medicine to develop and commercialize NGS-based assays and circulating tumor DNA tests.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Aug 28 | Sep 4 | NTRA | Natera, Inc. | Shares gained 22.4% through August 28 as Q2 revenue rose about 38%, testing volumes reached records, and management raised guidance. Japan approval, EU certification, and the expected August 30 Medicare coverage determination provide concrete near-term catalysts. | Closed | +0.6% |
| Jun 24 | Jul 1 | NTRA | Natera, Inc. | Strong near-term momentum and catalysts: stock up about 30% over 21 trading days to the highest close in the window; Q1 revenue grew about 39% YoY, management raised FY26 revenue outlook, FDA approved Signatera CDx in bladder cancer, and NCCN added ctDNA MRD testing to bladder cancer guidelines. | Closed | +6.3% |